Completed PHASE3 INTERVENTIONAL 2-arm NCT00817063

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema (HANDEL)

Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy

Sponsor: Basilea Pharmaceutica

Conditions Eczema

Updated 9 times since 2017 Last updated: Apr 10, 2020 Started: Jan 8, 2009 Primary completion: Apr 26, 2012 Completion: Apr 26, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Eczema, this trial is completed. The trial is conducted by Basilea Pharmaceutica and has accumulated 9 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
May 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jun 2018 — May 2020 [monthly]

Completed PHASE3
Dec 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Dec 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Basilea Pharmaceutica
Stiefel, a GSK Company

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Arlington Heights, United States , Belleville, United States , Bellingham, United States , Birmingham, United States , Burlington, United States , Chapel Hill, United States , Cincinnati, United States , Dallas, United States , Edina, United States and 57 more locations